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Glucocorticoids (GCs) are widely prescribed therapeutics for the treatment of
inflammatory diseases, and endogenous GCs play a key role in immune regulation.
Toll-like receptors (TLRs) enable innate immune cells, such asmacrophages, to recognize
a wide variety of microbial ligands, thereby promoting inflammation. The interaction of
GCs with macrophages in the immunosuppressive resolution phase upon prolonged
TLR activation is widely unknown. Treatment of human alveolar macrophages (AMs)
with the synthetic GC dexamethasone (Dex) did not alter the expression of TLRs −1,
−4, and −6. In contrast, TLR2 was upregulated in a GC receptor-dependent manner,
as shown by Western blot and qPCR. Furthermore, long-term lipopolysaccharide
(LPS) exposure mimicking immunosuppression in the resolution phase of inflammation
synergistically increased Dex-mediated TLR2 upregulation. Analyses of publicly available
datasets suggested that TLR2 is induced during the resolution phase of inflammatory
diseases, i.e., under conditions associated with high endogenous GC production.
TLR2 induction did not enhance TLR2 signaling, as indicated by reduced cytokine
production after treatment with TLR2 ligands in Dex- and/or LPS-primed AMs. Thus,
we hypothesized that the upregulated membrane-bound TLR2 might serve as a
precursor for soluble TLR2 (sTLR2), known to antagonize TLR2-dependent cell actions.
Supernatants of LPS/Dex-primed macrophages contained sTLR2, as demonstrated by
Western blot analysis. Activation of metalloproteinases resulted in enhanced sTLR2
shedding. Additionally, we detected full-length TLR2 and assumed that this might
be due to the production of TLR2-containing extracellular vesicles (EVs). EVs from
macrophage supernatants were isolated by sequential centrifugation. Both untreated
and LPS/Dex-treated cells produced vesicles of various sizes and shapes, as shown by
cryo-transmission electron microscopy. These vesicles were identified as the source of
full-length TLR2 in macrophage supernatants by Western blot and mass spectrometry.
Flow cytometric analysis indicated that TLR2-containing EVs were able to bind the TLR2
ligand Pam3CSK4. In addition, the presence of EVs reduced inflammatory responses
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in Pam3CSK4-treated endothelial cells and HEK Dual reporter cells, demonstrating that
TLR2-EVs can act as decoy receptors. In summary, our data show that sTLR2 and full-
length TLR2 are released by macrophages under anti-inflammatory conditions, which
may contribute to GC-induced immunosuppression.
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INTRODUCTION
Glucocorticoids (GCs) represent the most effective anti-
inflammatory drugs in the therapy of inflammatory lung diseases.
Genes that are upregulated by GC treatment, such as dual-
specificity phosphatase 1 (DUSP1), GC-induced leucine zipper
(GILZ), and interleukin (IL)-10, are highly immunosuppressive
and contribute to the overall effect of GC treatment (1–3).
Alveolar macrophages (AMs) are the tissue-resident
macrophages in the lung alveolar space. They represent the
first line of defense against pathogens in the lower airspace
and recognize microbial ligands via pattern recognition
receptors (4, 5). Toll-like receptors (TLRs) are the major pattern
recognition receptors of the innate immune system that sense a
wide range of “danger” signals or pathogen-associated molecular
patterns (PAMPs) (6–8).
To date, 10 TLRs have been identified in humans. Surface-
expressed TLRs (i.e., TLR1,−2,−4,−5,−6, and−10) recognize
bacterial, fungal, and parasitic PAMPs, whereas endosomal TLRs
(i.e., TLR3, −7/−8, and −9) sense nucleic acids of viral or
bacterial origin. After recognition and binding of a specific
PAMP, TLRs induce an intracellular signaling cascade that
culminates in the activation of the activator protein (AP)-
1, nuclear factor (NF)-κB, and interferon regulatory factors
(IRFs). These signaling cascades result in the secretion of pro-
inflammatory factors that ultimately protect the host from
microbial infection (6, 9).
Although GCs usually dampen TLR signaling, GC-mediated
induction of TLR2 has for example been shown in dendritic cells
(10), THP-1 macrophages (11), and AMs (12). TLR2 recognizes
a wide variety of pathogens, including bacteria, viruses, fungi,
Abbreviations: ACTB, beta actin; ADAM, a disintegrin and metalloproteinase;
AFC, 7-amino-4-trifluoromethylcoumarin; AMs, alveolar macrophages; ANXA1,
Annexin A1; AP-1, activator protein-1; APC, allophycocyanine; CCL, CC-
chemokine ligand; COX2, cyclooxygenase-2; CXCL, C–X–C motif ligand; Dex,
dexamethasone; DMEM, Dulbecco’s modified Eagle medium; DUSP1, dual-
specificity phosphatase-1; EVs, extracellular vesicles; FCS, fetal calf serum; FITC,
fluorescein isothiocyanate; flTLR, full length TLR; FPR2, formyl peptide receptor
2; GC, glucocorticoid; GILZ, glucocorticoid-induced leucine zipper; HEK, human
embryonic kidney; HKSA, heat-killed Staphylococcus aureus; ICAM1, intercellular
adhesion molecule 1; IL, interleukin; IL1RN, IL1 receptor antagonist; IFN,
interferon; IRFs, interferon regulatory factors; LPS, lipopolysaccharide; LTA,
lipoteichoic acid; MMP, matrix metalloproteinase; NF-κB, nuclear factor-κB;
NOS2, nitric oxide synthase 2; NTA, nanoparticle tracking analysis; MAPK,
mitogen-activated protein kinase; PE, phycoerythrin; MARCO, macrophage
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Poly(I:C), polyinosinic:polycytidylic acid; PRR, pattern recognition receptor;
RPMI, Roswell Park Memorial Institute; SELE, selectin E; STAT, signal transducer
and activator of transcription; sTLR, soluble TLR; TCA, trichloroacetic acid;
TEM, transmission electronmicroscopy; TNF, tumor necrosis factor; TLR, toll-like
receptor; VCAM1, vascular cell adhesion molecule 1; VCAN, versican.
mycobacteria, and parasites. Unlike other TLRs, the formation of
TLR2 heterodimers with other TLR family members (i.e., TLR1,
TLR6, or TLR10) or non-TLR cellular molecules (e.g., CXCR4
or scavenger receptors) is a prerequisite for the initiation of cell
activation (13).
Since TLR2 activity plays a prominent role in the pathogenesis
of numerous acute and chronic inflammatory diseases, its
activation has to be tightly regulated. In general, negative
regulation of TLR signaling can be mediated by soluble factors,
including soluble TLRs (sTLR) that act as decoy receptors
and bind to PAMPs in the extracellular space, preceding
their engagement with specific PRRs and reducing TLR
signaling efficiency (14–16). sTLR2 is produced via proteolytic
cleavage of the TLR2 trans-membrane protein, also referred
to as ectodomain shedding, by disintegrin metalloproteinases
(ADAMs) (17). Elevated sTLR2 plasma levels were observed
in experimental models of human endotoxemia and sepsis
patients and have therefore been suggested as a biomarker
for infections (18, 19).
Sepsis represents a life-threatening systemic inflammation
caused by bacterial infections. If sepsis patients survive the acute
inflammatory response, compensatory mechanisms result in
profound immunosuppression, often leading to lethal secondary
infections. Several critical factors have been identified that
contribute to the transition of the pro-inflammatory phase
into the immunosuppressive phase, including endogenous GCs
(1, 20, 21). In addition, prolonged exposure to bacterial
components, such as lipopolysaccharide (LPS), skews monocytes
and macrophages toward a hypo-responsive state termed LPS
tolerance. LPS-tolerant cells are characterized by a decreased
ability to produce pro-inflammatory mediators whereas their
expression of mediators involved in immunosuppression and
wound healing is elevated (20).
In the present study, we examined TLR2 expression in
primary human AMs after GC administration and in chronic
inflammation, as mimicked by prolonged LPS treatment.
MATERIALS AND METHODS
Materials
RPMI1640 (#R0883), DMEM (#D6546), trypsin/EDTA (#T3924),
fetal calf serum (FCS, #F7524), penicillin / streptomycin
(#P433), kanamycin (#K0254), and glutamine (#G7513) were
from Sigma-Aldrich. Endothelial cell growth media (#C-22010)
including supplement mix (#C-39215) were from PromoCell.
The anti-TLR2 antibody used for Western blot analysis
was obtained from Abcam (EPNCIR133, #ab108998). The
Phospho-p38 MAPK (Thr180/Tyr182, 3D7, #9215) and total
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p38 MAPK (#9212, polyclonal) antibodies were from Cell
Signaling. The anti-tubulin antibody (#T9026) was obtained
from Sigma-Aldrich. Anti-rabbit IRDye 680- and anti-mouse
IRDye 800-conjugated secondary antibodies were from LI-COR
Biosciences (#926-68071, #926-32210). The anti-rabbit IRDye
800-conjugated secondary antibody was from Rockland (#612-
132-120). APC-labeled anti-TLR2 and the respective isotype
control were from ThermoFisher Scientific (TL2.1, # 17-9922-
41; IgG2a kappa Isotype Control #17-4724-81). FITC anti-
CD9 (HI9a, #BLD-312103), FITC anti-CD63 (H5C6, #BLD-
353005), and the respective isotype control (MOPC-21, #BLD-
400109) were purchased from Biozol. The Zombie YellowTM
Fixable Viability Kit (#423103) was from BioLegend. Ultrapure
LPS from Escherichia coli K12 (#tlrl-peklps), Pam3CSK4 (#tlrl-
pms), rhodamine-labeled Pam3CSK4 (#tlrl-rpms), Pam2CSK4
(#tlrl-pm2s), heat-killed Staphylococcus aureus (#tlrl-hksa),
lipoteichoic acid (LTA, # tlrl-pslta), normocin (#ant-nr-1), and
zeocin (#ant-zn-1) were obtained from Invivogen. Phorbol
12-myristate 13-acetate (PMA, # 524400) was from Cayman
Chemical. Dexamethasone (#D8893) was obtained from Sigma-
Aldrich. Dexamethasone stock solutions were either prepared
in DMSO or ethanol (EtOH), and the appropriate vehicle
control is indicated in the figure legends. Alternatively, water-
soluble dexamethasone 21-phosphate disodium salt (Sigma-
Adrich, #D1159) was dissolved in medium, and untreated cells
served as a control (Figures 6C,D, 7, and 8). Primers and
dual-labeled probes were from Eurofins MWG Operon. Taq
polymerase (5 U/µL, #E00007), Taq buffer (#B0005), and the
dNTP mix (#D0056) were from Genscript. Other chemicals
were obtained from either Sigma-Aldrich or Carl Roth unless
stated otherwise.
Cell Culture
Cell Lines
THP-1 (#TIB202) and L929 cells (#CRL-6364) were obtained
from ATCC and grown in RPMI 1640 supplemented with 10%
FCS, 100 U/mL penicillin G, 100µg/mL streptomycin, and
2mM glutamine. THP-1 were differentiated into macrophage-
like cells by treatment with PMA (100 nM) for 48 h. HEK-DualTM
hTLR2 reporter cells (Invivogen, #hkd-htlr2ni) were grown in
DMEM supplemented with 10% FCS, 2mM glutamine, 50 U/mL
penicillin G, 50µg/mL streptomycin, 100µg/mL normocin, and
100 µg/mL zeocin.
Human Alveolar Macrophages (AMs)
Human lung tissue was obtained from patients undergoing
lung resection. The use of human material was reviewed and
approved by the local ethics committee (State Medical Board of
Registration, Saarland, Germany; permission no. 213/06). The
informed consent of all participating subjects was obtained. AM
isolation was performed according to a previously described
method (4, 22, 23) with minor modifications. After visible
bronchi were removed, the lung tissue was chopped and washed
with PBS (137mM NaCl, 2.7mM KCl, 10.1mM Na2HPO4,
1.8mM KH2PO4, pH 7.4). The washing buffer was collected
and centrifuged (15min, 350 x g). Remaining erythrocytes were
lysed by briefly resuspending the pellet in autoclaved water,
followed by immediate washing with PBS and centrifugation.
Cells were resuspended in AM medium (RPMI 1640 containing
5% FCS, 100 U/mL penicillin G, 100µg/mL streptomycin, and
2mM glutamine). Unless stated otherwise, AMs were seeded at
a density of 0.5–1 × 106 cells/well into a 12- or 6-well plate
and incubated at 37◦C for 2 h, washed with PBS, and cultured
overnight before further use. AM preparations were 95% pure as
judged by flow cytometric analysis of intracellular CD68 (4, 24).
Human Umbilical Vein Endothelial Cells (HUVECs)
HUVECs were isolated from umbilical cords provided by
the Klinikum Saarbrücken (Saarbrücken, Germany; ethics
committee permission no. 131/08). The informed consent of
all donors was obtained. HUVEC isolation and culture was
performed as described previously (25, 26). In brief, HUVECs
were isolated by digestion of umbilical veins with 100 mg/L
collagenase A (Roche, Mannheim, Germany). Cells were grown
in endothelial growth medium with supplement mix, 100 U/mL
penicillin G, 100µg/mL streptomycin, 50 mg/mL kanamycin,
and 10% FCS. For all experimental procedures, HUVECs were
used in passage three. Cells were detached with trypsin/EDTA,
seeded at a density of 1 × 105 cells per well in a 24-well plate
and incubated overnight before further treatment. HUVECs were
>95% pure, as assessed by flow cytometry using an antiserum
against the von Willebrand factor (27).
TNF-α Bioassay
TNF-α concentrations in cell culture supernatants were
quantified by bioassay as previously described (28). L929
cells were seeded into a 96-well plate (3 × 104 cells per well)
and incubated overnight at 37◦C, 5% CO2. The medium was
discarded, and 100 µL of actinomycin D solution (1µg/mL in
growth medium) was added. After incubation for 1 h at 37◦C,
AM supernatants (100 µL per well) were added. Dilution series
of recombinant human TNF-α (100–2,500 pg/mL) were run
alongside the samples to generate a standard curve. The plate was
incubated for 24 h at 37◦C, followed by incubation with MTT
solution (0.5 mg/mL in medium) for 2 h. The supernatant was
discarded, and cells were lysed in 100 µL DMSO. Absorbance
measurements were carried out at 550 nm with 630 nm as the
reference wavelength using a microplate reader (Tecan Sunrise).
RNA Isolation, Reverse Transcription, and
Quantitative RT-PCR
Total RNA was isolated using the RNeasy Plus Mini Kit
(Qiagen, #74134) or the High Pure RNA Isolation Kit (Roche, #
11828665001), and RNA was reverse transcribed using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
#4368813) according to the manufacturer’s instructions. The
cDNA was diluted with TE buffer (Applichem, #A0386) before
use. The CFX96 TouchTM Real-Time PCRDetection System (Bio-
Rad) was used for real-time RT-PCR. For ACTB, CXCL10, IL10,
TLR1, TLR2, TLR4, TLR6, and TNF, one 25 µL reaction mix
contained 2.5U Taq polymerase, 500 nM sense and antisense
primers, 60-100 nM probe, 200µM dNTPs, 3-4mM MgCl2, 2.5
µL 10x Taq buffer, 3 µL Template, and molecular biology grade
water (Applichem, #A7398). The reaction conditions were 95◦C
for 8min followed by 40 cycles of 15 s at 95◦C, 15 s at a reaction
dependent temperature varying from 57 to 60◦C, and 15 s at
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FIGURE 1 | Dexamethasone induces TLR2 in AMs. (A–E) AMs were incubated with solvent control (0.1% DMSO, Co) or dexamethasone (Dex, 1µM) for up to 24 h
(A–D) or at the indicated concentrations for 4 h (E). (E–G) AMs were preincubated with the GR inhibitor RU486 (10µM) or solvent control (0.1% EtOH) and treated
(Continued)
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FIGURE 1 | with Dex (1µM) for 24 h. Data from at least three independent experiments performed in duplicate with cells from different donors are presented as
means ± SEM. TLR expression was measured by or qPCR (A,B,E,F) or Western blot (C,D,G,H). (A) TLR expression upon Dex treatment was normalized to the TLR
expression values for the respective vehicle-treated control (indicated by the dotted line). (B–H) TLR2 expression in solvent-treated cells were set as 1. (C,G)
Representative blots. (D,H) Densitometric analysis. TLR2 signal intensities were quantified and normalized to the loading control tubulin. *p < 0.05, **p < 0.01, ***p <
0.001, ###p < 0.001 vs. vehicle-treated cells. p-values were generated by ANOVA with Bonferroni’s post-hoc test or Mann–Whitney U-test.
FIGURE 2 | TLR2 is overexpressed during the immunosuppressive phases of SIRS and sepsis. (A,B) Dataset GSE4607 was obtained from Gene Expression
Omnibus (GEO) and normalized using log2-RMA. The dataset included transcriptional profiles of human whole blood samples of 15 healthy controls, 27 patients with
non-infectious SIRS and 12 samples from patients with resolved non-infectious SIRS. Patients were classified as SIRS, or SIRS resolved (no longer meeting criteria for
SIRS) on d3 after ICU admittance. (C,D) Dataset GSE8121 was retrieved from GEO and normalized using log2-RMA. The dataset included transcriptional profiles of
human whole blood samples of 15 healthy controls and 30 patients with sepsis. Samples were obtained at d1 and d3 after admittance to the ICU. The statistical
significance was determined by the Kolmogorov–Smirnov test.
72◦C. For ADAM10, ADAM17, CCL2, DUSP1, FPR2, ICAM,
MMP9, SELE, and VCAM detection, the 5x HOT FIREPol R©
EvaGreen R© qPCR Mix Plus (Solis Biodyne, #08-25) was used
according to the manufacturer’s recommendations. Primer and
probe sequences, as well as specific reaction conditions, are
given in Supplementary Table 1. Standard curves were generated
by using a dilution series of the PCR product cloned into
pGEMTeasy (Promega, #A1360) (23, 28, 29). All samples
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FIGURE 3 | Long-Term LPS exposure upregulates TLR2 in AMs. (A–D) AMs were incubated with LPS (100 ng/mL) for 24 h (A) or the indicated time points (B–D).
TLR expression was measured by qPCR (A,B) or Western blot (C,D). (A) TLR expression was normalized to the TLR expression values for the respective
(Continued)
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FIGURE 3 | vehicle-treated control which was set as 1 (indicated by the dotted line). (E–F) AMs were treated with LPS (100 ng/mL), Pam3CSK4 (Pam3, 100 ng/mL)
or Poly(I:C) (PIC, 1µg/mL) for 24 h. TLR2 expression was analyzed by qPCR (E) and Western blot (F). (G,H) Long-Term LPS exposure results in LPS tolerance. AMs
were pretreated with LPS (100 ng/mL) for 24 h and restimulated with LPS (1µg/mL) for 2 h. TNF, CXCL10, IL10, MMP9, FPR2, and TLR2 mRNA expression levels
were determined by qPCR. NT/NT, not treated; NT/LPS, LPS stimulation without pretreatment; LPS/NT, LPS pretreatment only; LPS/LPS, LPS pretreatment followed
by LPS stimulation. Data from at least three independent experiments performed in duplicate with cells from different donors are shown and are presented as x-fold of
solvent-treated cells ± SEM. #p < 0.05, ###p < 0.001 vs. untreated cells, *p < 0.05, **p < 0.01, ***p < 0.001 as indicated, §p < 0.05 vs. Pam3-treated cells.
p-values were generated with ANOVA and Bonferroni’s post-hoc test.
and standards were analyzed in triplicate. All samples were
normalized to the housekeeping gene ACTB.
Extracellular Vesicles (EVs)
Isolation
AMs or differentiated THP-1 cells were incubated for 3 d in
FCS-free medium in the presence or absence of LPS (100 ng/mL)
and/or dexamethasone (1µM). EVs were purified from cell
culture supernatants by sequential centrifugation as previously
described (30). For THP-1-derived vesicles, 5 × 107 cells
were used per preparation. After differentiation for 48 h, cells
were washed with PBS, and FCS-free medium was added.
Serum deprivation did not result in increased cell death, as
indicated by caspase 3 assay and Zombie Yellow staining
(Supplementary Figure 1).
Cell culture supernatants were collected and centrifuged at
300 × g for 10min to remove remaining cells, followed by
removal of dead cells and large cell debris by centrifugation
at 2,000 × g for 10min and 10,000 × g for 30min.
Supernatants were transferred into stable polycarbonate tubes
(# 4416, Laborgeräte Beranek), and EVs were collected by
ultracentrifugation at 100,000 x g for 90–120min in an L70
ultracentrifuge with a 70Ti rotor (Beckman Coulter). EVs were
washed with 25mL sterile-filtered PBS and pelleted again by
ultracentrifugation (100,000 × g, 90–120min). The EV pellet
was then resuspended in sterile-filtered PBS (AMs: 200–350
µL; THP-1: 200 µL) and stored at −80◦C in protein LoBind
microcentrifuge tubes (# Z666505, Eppendorf).
Nanoparticle Tracking Analysis (NTA)
For nanoparticle tracking analysis (NTA), EV suspensions were
diluted 1:200 in sterile-filtered PBS. 300–500 µL of the dilution
were injected into the sample chamber of a NanoSight LM10
(NanoSight Ltd). A video of 60 s was recorded and analyzed by
the NTA software Nanosight NTA 2.3 to calculate vesicle size
and concentration.
Protein Concentration
Total protein concentrations were determined with the Pierce
BCA protein assay kit (ThermoFisher Scientific, #23225) using
a GloMax R© Discover Multimode Microplate Reader (Promega)
according to the manufacturer’s instructions.
Cryo-Transmission Electron Microscopy (TEM)
A 3 µL droplet of the aqueous EV dilution was placed onto a
holey carbon covered TEM grid (Plano, type S147-4), plotted
onto a thin liquid film for 2 s and plunged into a bath of liquid
ethane at −165◦C using a Gatan CP3 cryoplunger (Pleasanton).
The frozen sample was transferred under liquid nitrogen to a
Gatan cryo-TEM sample holder (model 914) and investigated
at −173◦C by low-dose bright-field imaging TEM (JEOL JEM-
2100 LaB6). A Gatan Orius SC1000 CCD camera was used for
image acquisition.
Proteomics
Thirty micrograms of EV protein were precipitated by
trichloroacetic acid (TCA) precipitation with an end
concentration of 20% TCA. Samples were washed thrice
with acetone. After a final centrifugation of 15min in a SeedVac
Plus concentrator (Savant, Thermo Fisher, Waltham, USA),
samples were resuspended in 2x Lämmli buffer (4% SDS, 20%
glycerol, 120mM Tris-HCl (pH 6.8), 0.02% bromophenol blue
in Millipore water) and denatured at 95◦C for 5min. Proteins
were separated on NuPAGE
R©
10% gels and prepared for
mass spectrometry as described previously (31). Three protein
bands per sample were cut out of the gel and incubated with
porcine trypsin (Promega, #V5111) for in-gel digestion at 37◦C
overnight. Resulting peptides were extracted twice by shaking
the gel pieces in aqueous extraction buffer (2.5% formic acid,
50% acetonitrile). Extracted peptides were concentrated via
vacuum centrifugation and resuspended in 0.1% formic acid.
Six microliters of each tryptic peptide extract were analyzed by
online nanoflow LC-HR-MS/MS (Ultimate 3000 RSLC nano
system equipped with an Ultimate3000 RS autosampler coupled
to an LTQ Orbitrap Velos Pro, ThermoFisher Scientific) as
described previously (31). Peptides were analyzed at a flow
rate of 200 µL/min with buffer A (water and 0.1% formic
acid) and B (90% acetonitrile and 0.1% formic acid) using
the gradient given in Supplementary Figure 2. Fragmented
peptides were identified using software Proteome Discoverer
1.4 (ThermoFisher Scientific) and database SwissProt 2015_01
(species human). For further data evaluation, software Scaffold4
(version 4.8.3) was used. In order to allow expression of x-fold
values if a protein was absent in one of the treatments, log2
fold changes were calculated as log2[(mean of unique spectrum
counts in EVLPS+Dex) + 0.1) / (mean of unique spectrum
counts in EVCo + 0.1)]. The mass spectrometry proteomics data
have been deposited to the ProteomeXchange Consortium via
the PRIDE partner repository (32) with the dataset identifier
PXD013977 and 10.6019/PXD013977.
Flow Cytometry
For analysis of EV surface proteins by flow cytometry, vesicles
were coupled to the surface of 4µm aldehyde/sulfate latex beads
(Invitrogen, #A37304). In detail, an amount of EVs resembling
10 µg protein or the same amount of the negative control BSA
were allowed to bind to 10 µL latex beads for 15min at room
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temperature in a final volume of 100 µL in PBS. After adding
400 µL PBS, samples were incubated for 1 h at room temperature
with gentle shaking. The reaction was stopped by adding 500
FIGURE 4 | Synergistic upregulation of TLR2 by dexamethasone and LPS.
AMs were preincubated with the GR inhibitor RU486 (10µM) or solvent control
(0.1% EtOH) and treated with LPS (100 ng/mL), Dex (1µM) or both for 24 h.
TLR2 expression was measured by qPCR (A) or Western blot (B,C). (B)
Representative blot. (C) Densitometric analysis. TLR2 signal intensities were
quantified, normalized to tubulin values, and expressed as x-fold of untreated
cells. (A,C) Data from at least three independent experiments performed in
duplicate with cells from different donors are presented as means + SEM.
*p < 0.05, **p < 0.01. p-values were generated by ANOVA with Bonferroni’s
post-hoc test.
µL 200mM glycine, followed by incubation for 30min at room
temperature. EV- or BSA-coupled beads were washed three times
with 1% BSA in PBS, with centrifugation steps at 2,000 × g
for 3min in between. Samples were stained with fluorescently
labeled antibodies directed against TLR2 or the EV markers CD9
and CD63 or the respective isotype controls on ice in the dark.
Staining with rhodamine-labeled Pam3CSK4 was performed
accordingly. Details are given in Supplementary Table 2. After
30min, samples were washed twice with 1% BSA in PBS and
analyzed on a BD LRS Fortessa (BD Biosciences) using BD
FACSDiva 8.0. For graphical illustrations, BD FACSuite (version
1.0) software was used.
Western Blotting
For whole cell analysis, cells were lysed in lysis buffer (50mM
Tris-HCl, 1% (m/v) SDS, 10% (v/v) glycerol, 5% (v/v) 2-
mercaptoethanol, 0.004% (m/v) bromphenol blue) supplemented
with a protease inhibitor mix (cOmplete; Roche Diagnostics,
#04693124001). Samples were sonicated, centrifuged at 10,000
× g for 10min at 4◦C, and stored at −80◦C until further use
(23, 28, 29, 33). Cell culture supernatants from AMs cultured in
a 12 well plate (5 × 105 cells per well in 300 µL medium) were
concentrated 10x by centrifugation at 15,000 × g for 8min in
Vivaspin
R©
500 tubes with 10 kDa cut off (Sartorius #VS0102).
Concentrated supernatants (21 µL per lane), as well as isolated
EVs (5 × 109 vesicles per lane), were supplemented with a 4x
loading buffer (Carl Roth, Roti
R©
-load 1, #K929.1). Before gel
electrophoresis, all samples were denatured at 95◦C for 5min and
subsequently kept on ice before gel loading.
SDS-polyacrylamide gel electrophoresis (PAGE) was carried
out using polyacrylamide gels (4% stacking gel, 12% resolving
gel) and the Mini-PROTEAN
R©
system (Bio-Rad). A prestained
protein ladder was used to estimate the molecular mass (#26616,
ThermoFisher Scientific). Samples were transferred onto an
Immobilon FL-PVDF membrane (# IPFL00010, Millipore-
Merck, Darmstadt, Germany) using a Mini Trans-Blot
R©
Cell
(Bio-Rad). The membrane was blocked for 1–4 h at room
temperature in blocking buffer for near-infrared fluorescent
Western blotting (#MB-070, Rockland) to saturate unspecific
binding sites. Subsequently, the membrane was incubated with
primary antibody dilutions (1:500–1:2,000 in Rockland blocking
buffer) at 4◦C, either overnight or for 48 h. After thorough
washing with PBST (PBS + 0.1% Tween-20), the membrane
was stained with IRDye680- or IRDye800-conjugated secondary
antibodies (1:5,000–1:10,000) diluted in blocking buffer for 1.5-
2 h at room temperature, washed again, and signals were detected
and quantified using an Odyssey imager and software (LI-COR
Biosciences). For densitometric analysis, signal intensities were
normalized to the loading control tubulin except for pp38 which
was normalized to values for total p38.
Viability Assays
Caspase 3-Like Assay
Cells were washed twice with ice-cold PBS. Seventy microliters
ice-cold lysis buffer (25mM HEPES, 5mM MgCl2, 1mM
EGTA, 0.1% [v/v] Triton X-100) were added, and the samples
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were stored at −80◦C. After thawing on ice, the lysates were
centrifuged (14,000 × g, 10min, 4◦C) and 10 µL of the
supernatant were transferred to a black 96 well plate (TPP). 90µL
substrate solution (55µM of fluorogenic substrate Ac-DEVD-
AFC (Enzo, #ALX-260-032-M005) 50mM HEPES, 0.1% [w/v]
CHAPS, 1% [w/v] sucrose, 10mM DTT, pH 7.5) were added,
FIGURE 5 | Impaired response toward TLR2 ligands in LPS- and/or
Dex-pretreated AMs. (A) AMs were preincubated with LPS (100 ng/mL), Dex
(1µM), or both for 24 h and treated with Pam3CSK4 (Pam3, 1µg/mL, 4 h).
TNF secretion was assessed by TNF bioassay. (B,C) Primary human AMs were
incubated with LPS (100 ng/mL, 24 h) before restimulation with TLR2 ligands
for 2 h. LTA: lipoteichoic acid (5µg/mL), HKSA: heat-killed S. aureus (108
cells/mL), Pam2: Pam2CSK4 (1µg/mL), Pam3: Pam3CSK4 (1µg/mL). TNF
(B) and TLR2 (C) mRNA levels were determined by qPCR. Data from at least
three independent experiments performed in duplicate with cells from different
donors are presented as means + SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
p-values were generated by ANOVA with Bonferroni‘s post-hoc test.
and the production of free 7-amino-4-trifluoro-methyl coumarin
(AFC) at 37◦C was determined by fluorescence measurement
(excitation: 405 nm; emission: 495-505 nm) using a GloMax
R©
Discover Multimode Microplate Reader (Promega).
Zombie Yellow Staining
Cells were stained with the Zombie YellowTM Fixable Viability
Kit as recommended by the supplier. Samples were analyzed
on a BD LRS Fortessa (BD Biosciences) using BD FACSDiva
8.0 software.
HEK-Dual hTLR2 Reporter Assay
HEK-DualTM hTLR2 reporter cells express TLR2, an NF-κB/AP1-
inducible secreted embryonic alkaline phosphatase (SEAP)
reporter gene, and a secretable luciferase reporter gene (Lucia
luciferase) placed under the control of the endogenous IL-
8 promoter.
Cells were seeded into 96-well plates (5 × 105 cells/well) and
immediately treated as indicated to monitor TLR2-dependent
activation. After 24 h, supernatants were collected, and the
activity of Lucia luciferase was determined using the QuantiLuc
reagent (Invivogen, #rep-qlc1) according to the supplier’s
instructions. SEAP activity could not be used as a readout
parameter in our setting because EVs interfered with the assay
(data not shown).
Analysis of Publicly Available Datasets
Datasets were obtained from Gene Expression Omnibus (GEO)
and normalized using log2-RMA. Dataset GSE4607 included
transcriptional profiles human whole blood samples of 15
healthy controls, 27 patients with non-infectious SIRS, and
12 samples from patients with resolved non-infectious SIRS.
Patients were classified as SIRS or SIRS resolved (no longer
meeting criteria for SIRS) on d3 after ICU admittance. Dataset
GSE8121 included transcriptional profiles of human whole blood
samples of 15 healthy controls and 30 patients with sepsis.
Samples were obtained at d1 and d3 after ICU admission.
Statistical significances were determined by the Kolmogorov–
Smirnov test. Detailed information about the patient cohort
is given in the GEO database and the corresponding original
publications (34, 35).
Statistics
All experiments were performed at least three times, and at least
two replicates were analyzed for all experiments unless stated
otherwise. Data distribution was determined by the Shapiro-
Wilk test. For normally distributed data, means of two groups
were compared with non-paired two-tailed Student’s t-test or
one sample t-test where applicable. For data that were not
normally distributed, means of two groups were compared
using the Mann-Whitney test. Means of more than two groups
were compared by one-way ANOVA with Bonferroni’s post hoc
test (normal distribution) or Kruskal–Wallis ANOVA followed
by Mann-Whitney test (no normal distribution). Statistical
significance was set at p < 0.05, p < 0.01, or p < 0.001.
Data analysis was performed using Origin software (OriginPro
2015G; OriginLab).
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RESULTS
Upregulation of TLR2 by GCs
Human AMs express the surface TLRs −1, −2, −4, and −6 (4).
Thus, we initially quantified the expression of these receptors
after treatment with the GC dexamethasone (Dex) for 24 h by
qPCR. Whereas Dex administration had no significant effect
on TLR1, −4, and −6 mRNA levels, TLR2 was highly induced
(Figure 1A). Further analysis showed that TLR2 upregulation
was already detectable 4 h after treatment (Figure 1B), and TLR2
protein production was maximal after 16 h, as shown byWestern
blot analysis (Figures 1C,D). Dex induced TLR2 starting at
a concentration of 100 nM (Figure 1E). Next, we evaluated
whether Dex binding to the GR is necessary for TLR2 induction.
To this end, we pretreated AMs with RU486, a specific GR
antagonist, before Dex was added. RU486 completely abrogated
Dex-mediated TLR2 mRNA and TLR2 protein upregulation,
indicating a GR-dependent mechanism (Figures 1F–H).
TLR2 Induction in SIRS and Sepsis
In vivo, endogenous GCs contribute to immunosuppression
occurring at later stages of inflammatory processes (1, 20, 21).
Analyses of publicly available datasets showed that TLR2 mRNA
was induced in whole blood samples from pediatric patients
suffering from SIRS (Figures 2A,B) or sepsis (Figures 2C,D). In
both groups, TLR2 induction was paralleled by the upregulation
of genes involved in the resolution of inflammation or wound
healing (MMP9, MARCO, VCAN, FPR2, IL1RN, ANXA1, IL10,
DUSP1), whereas the gene expression of pro-inflammatory
factors (TNF, IL12B, IL6, IFNG, CXCL10, COX2, NOS2) was not
elevated compared with healthy controls, suggesting the onset of
anti-inflammatory feedback mechanisms.
TLR2 Induction by LPS in the Absence or
Presence of GCs
Prolonged exposure to LPS, which often occurs in sepsis, can
result in LPS tolerance in macrophages and monocytes, thereby
contributing to immunosuppression (20). Thus, we wondered
whether TLR2 levels might be altered by LPS stimulation.
LPS treatment for 24 h potently induced TLR2, but not TLR1,
TLR4, and TLR6 mRNA expression in AMs (Figure 3A). TLR2
mRNA and TLR2 protein upregulation were most evident at
later time points after LPS addition (Figures 3B–D). Other
FIGURE 6 | TLR2 in AM supernatants. (A,B) AMs were incubated with solvent control (0.1% DMSO), LPS (100 ng/mL), Dex (1µM), or LPS+Dex for 24 h.
4-aminophenylmercuric acetate (APMA, 10µM) was added to the indicated samples 5 h before supernatants were harvested. Soluble TLR2 (sTLR2) and full-length
TLR2 (flTLR2) were detected in the supernatants by Western blot. (A) representative blot. (B) Relative sTLR2/TLR2 signal intensities are presented as means + SEM
(n = 5). *p < 0.05 (Student’s t-test). (C,D) Cells were either left untreated (Co) or treated with LPS (100 ng/mL) + Dex (1µM) for 3 days, and EVs were isolated by
sequential centrifugation. (C) Representative cryo-TEM images of EVs from untreated (Co) and LPS+Dex-treated cells. (D) Representative Western blot analysis for
TLR2 in AM supernatants before and after ultracentrifugation (UC) and in EVs is shown (n = 5).
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FIGURE 7 | Characterization of THP-1 vesicles. Cells were incubated with medium only (Co), LPS (100 ng/mL), Dex (1µM), or LPS+Dex for 72 h and EVs were
isolated by sequential centrifugation. (A) Vesicles were visualized by cryo-TEM. Scale bar = 500 nm. (B,C) Average EV size (B) and concentration (C) were
(Continued)
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FIGURE 7 | determined by nanoparticle tracking analysis. Data are presented as means + SEM (n = 7). *p < 0.05, **p < 0.01. p-values were generated by
Mann–Whitney U-test. (D,E) EVs originating from differentially treated THP-1 cells were subjected to proteomics analysis (n = 3). (D) Overlap of identified proteins
among treatment groups. (E) TLR2 and EV marker distribution. Log2 values of unique spectrum counts are shown for all three independent preparations per
treatment. (F) Volcano plot of p-value vs. fold change in expression level in EVLPS+Dex vs. EVCo. Proteins that were upregulated at least 4-fold in EVLPS+Dex vs. EVCo
with a p < 0.01 are highlighted. (G) Representative Western blot result for TLR2 detection in THP-1 supernatant before and after ultracentrifugation (UC) and in EV
fractions (n = 3).
TLR ligands, i.e., the TLR2 ligand Pam3CSK4 and the TLR3
ligand Poly(I:C), also induced TLR2, although to a lesser
extent (Figures 3E,F). LPS-mediated TLR2 upregulation was
accompanied by LPS tolerance, as indicated by the inability
of LPS-primed AMs to produce the inflammatory cytokines
TNF and CXCL10 in response to repeated LPS stimulation
(Figure 3G). As seen in whole blood samples from sepsis patients
(Figure 2), TLR2 induction correlated with the overexpression
of genes associated with immunosuppression (IL10, FPR2) or
wound healing (MMP9) (Figure 3H).
We next evaluated whether the presence of both GCs and LPS
might elevate TLR2 expression even further. Indeed, we observed
that both compounds cooperatively induced TLR2 mRNA and
protein (Figures 4A–C). Binding of Dex to its receptor was
required for the cooperative regulation of TLR2 because the
GR antagonist RU486 blocked Dex-induced effects both in the
absence or presence of LPS. LPS-mediated upregulation of TLR2
was not affected by RU486 administration (Figures 4A–C).
We hypothesized that TLR2 upregulation might rescue TLR2
signaling in otherwise immunocompromised AMs. Therefore, we
treated AMs pretreated with LPS, Dex, or a combination of both
with the TLR2 ligand Pam3CSK4 and measured TNF levels in
AM supernatants. None of the pretreatment schemes sensitized
AMs toward Pam3CSK4. Quite in contrast, TLR2 signaling was
inhibited in each of the conditions tested (Figure 5A). Similar
effects were observed when we used different TLR2 ligands, i.e.,
lipoteichoic acid (LTA) and heat-killed Staphylococcus aureus
(HKSA), to stimulate LPS-tolerant AMs. The response to the
TLR1/6 ligand Pam2CSK4 showed a comparable tendency, but
the reaction to this ligand was heterogenous amongst cells from
different donors (Figure 5B). Interestingly, LTA treatment even
enhanced TLR2 induction in LPS-pretreated AMs (Figure 5C).
The lack of responsiveness toward TLR2 ligands in AMs that
highly expressed TLR2 suggested an entirely different function
of TLR2 in this context.
TLR2 in Macrophage Supernatants
We hypothesized that the upregulated membrane-bound TLR2
might serve as a precursor for sTLR2, known to antagonize
TLR2-dependent cell actions. Supernatants of LPS+Dex-primed
AMs indeed contained the soluble 83 kDa form of TLR2, as
indicated by Western blot analysis (Figure 6A). As previously
shown by Langjahr et al. (17), activation of metalloproteinases by
4-aminophenylmercuric acetate (APMA) resulted in enhanced
sTLR2 shedding (Figure 6B). sTLR2 is produced via proteolytic
cleavage of the TLR2 trans-membrane protein by ADAM10
and ADAM17 (17). These ADAMs were also expressed by
alveolar macrophages, and ADAM17 was even induced when
LPS and Dex were present (Supplementary Figure 3). Thus, an
involvement of ADAM17 in sTLR2 shedding is suggested.
Surprisingly, we also detected full-length TLR2 (flTLR2,
∼ 102 kDa) and assumed that this might be due to the
production of TLR2-containing extracellular vesicles (EVs).
Therefore, EVs from macrophage supernatants were isolated by
sequential centrifugation. Both untreated and LPS+Dex-treated
cells produced vesicles of various sizes (50–300 nm) and mostly
round in shape, as shown by cryo-TEM (Figure 6C). These
vesicles were identified as the source of full-length TLR2 in
macrophage supernatants, as indicated by Western blot analysis
(Figure 6D).
Vesicle Characterization
For vesicle characterization and functional analysis, we
used differentiated THP-1 cells as an easily accessible EV
source. THP-1-derived EVs were similar to AM-derived
EVs regarding size and shape (Figure 7A). Nanoparticle
tracking analysis (NTA) was used to determine the EV size
and concentration. Treatment schemes did not influence the
vesicle size (∼220 nm), but the number of vesicles slightly
increased with Dex- or LPS+Dex-treatment (Figures 7B,C).
This was not due to increased apoptosis, as determined by
caspase-3 activity (Supplementary Figure 1). Vesicle numbers
correlated with protein concentrations of the vesicle preparations
(Supplementary Figure 4).
EV preparations were analyzed by high-resolution tandem
mass spectrometry (MS/MS) to determine whether the treatment
scheme had an impact on vesicle composition. A total of 709
proteins was detected in each of the independent experiments,
and 401 proteins occurred in all four EV types (Figures 7D,E).
The preparations did not show differences in vesicle marker
abundance, and both exosome- and microvesicle-specific
markers (36, 37) were detected (Figure 7E). Several proteins
were enriched in EVs from LPS+Dex-treated cells (EVLPS+Dex),
including TLR2 (Figure 7F). As seen in AM-derived EVs, TLR2
was most abundant in EVLPS+Dex preparations when compared
with other treatment schemes (Figure 7G).
THP-1-derived EVs were further analyzed by flow cytometry.
To this end, vesicles were coupled to aldehyde/sulfate latex
beads. The presence of vesicle markers, tetraspanins CD9 and
CD63 (36, 38), indicated that the vesicles were attached to the
beads (Figures 8A,B). TLR2 staining confirmed that TLR2 was
present in EVLPS+Dex samples, but not in preparations from
vehicle-treated cells (EVCo) (Figures 8C,E). In addition, staining
of bead/EV complexes with fluorochrome-labeled Pam3CSK4
showed that EVLPS+Dex were able to bind the TLR2 ligand,
whereas EVsCo were not (Figures 8D,F).
To examine the functional implications of TLR2-EV
production, we treated primary human umbilical vein
endothelial cells (HUVECs) with a mix of Pam3CSK4 and
either EVCo or EVLPS+Dex. Subsequently, the expression of
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FIGURE 8 | TLR2-containing vesicles act as decoy receptors. Differentiated THP-1 cells were incubated with medium only (Co) or LPS (100 ng/mL) + Dex (1µM) for
72 h and EVs (EVCo and EVLPS+Dex, respectively) were isolated by sequential centrifugation. (A–F) Bead-bound EVs from untreated or LPS+Dex-treated
(Continued)
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FIGURE 8 | THP-1 cells were analyzed by flow cytometry. Unloaded latex beads served as controls. Histograms show bead counts vs. log fluorescence intensity.
(A,B) EV loading was confirmed by staining for vesicle markers CD9 (A) and CD63 (B). Representative histograms are shown (n = 3). (C–F) TLR2 staining and binding
of rhodamine-labeled Pam3CSK4 (Pam3). (C,D) Representative histograms. (E,F) Mean fluorescence intensities were expressed as x-fold of EVCo values + SEM (n =
3, duplicates). (G) Pam3-induced gene expression in HUVECs was measured by qRT-PCR. Pam3 was preincubated with the specified vesicles for 30min at 37◦C (2
× 1010 EVs/µg Pam3), and HUVECs were treated with the Pam3/EV mix (2 × 1010 EVs and 1 µg Pam3/mL) for 3 h. Data from 3 independent THP-1 vesicle
preparations and HUVEC donors are presented as a percentage of EVCo-treated cells + SEM. H: Pam3-induced CXCL8 promoter-dependent luciferase activity was
quantified in hTLR2 HEK-Dual cells. Cells were either treated with Pam3 only (1 ng/mL, Co) or co-treated with Pam3 (1 ng/mL) and the specified vesicles (5 × 109
EVs/ml) for 24 h. The Pam3/vesicle mix was preincubated for 30min at 37◦C before it was added to the cells. Data are expressed as percentage of Co-values + SEM
(n = 4, duplicates). *p < 0.05, **p < 0.01, n.s.: not significant. P-values were generated by ANOVA with Bonferroni‘s post-hoc test or Student’s t-test.
the chemokine CCL2 and the adhesion molecules ICAM,
VCAM, and SELE were measured. Pam3CSK4-induced CCL2
expression was decreased in HUVECs treated with ECVLPS+Dex
(Figure 8G). The expression of the three adhesion molecules
tended to be reduced, although not significantly so due to
high inter-individual differences between donors. Additionally,
TLR2-responsive HEK reporter cells expressing a luciferase
reporter gene under the control of the CXCL8 promoter were
used to study the influence of EVs on Pam3CSK4-induced
inflammatory responses. We found indeed that TLR2-containing
vesicles derived from LPS+Dex-treated cells were able to
inhibit Pam3CSK4-induced luciferase production (Figure 8H).
In summary, these data suggest that TLR2-EVs can exert
decoy functions.
DISCUSSION
AMs are one of the first lines of defense against the invasion
of airborne pathogens. The stimulation of TLRs triggers the
production of proinflammatory cytokines, which in turn activate
the hypothalamic-pituitary axis to induce the synthesis and
secretion of anti-inflammatory GCs by the adrenal cortex,
thereby limiting inflammation (39). Therapy of pulmonary
diseases, such as asthma and chronic obstructive pulmonary
disease, with inhaled GCs mimics the effects of endogenous
GCs, resulting in decreased production of pro-inflammatory
mediators by AMs (12).
Paradoxically, glucocorticoids have also been suggested
to enhance inflammation and innate immune responses,
particularly by upregulating TLR2 (40). An increase in TLR2
expression after GC administration was observed in many cell
types, including epithelial cells (41–43), keratinocytes (44, 45),
dendritic cells (10), and macrophages (11, 12, 45). Several studies
showed that TLR ligands or inflammatory cytokines cooperate
with GCs to induce TLR2 (12, 41–45). In line with our findings,
Ji et al. (12) reported that coadministration of the GC budesonide
and LPS resulted in elevated TLR2mRNA levels in human AMs,
whereas TLR4 was not affected.
Different mechanisms were suggested to underly the
cooperative induction of TLR2 by GCs and pro-inflammatory
stimuli. For example, Haemophilus influenzae-mediated TLR2
upregulation was enhanced by GCs via negative cross-talk
with the mitogen-activated protein kinase (MAPK) p38 (41).
Likewise, GC-mediated TLR2 induction was reported to
depend on p38 inhibition via the GC-inducible phosphatase
DUSP1 in keratinocytes and epithelial cells (44, 46). An
entirely different mechanism was suggested to drive TLR2
expression in TNF-α/GC-treated A549 cells, requiring the
collective recruitment of NF-κB, signal transducer and
activator of transcription (STAT) transcription factors, and
the GR to the TLR2 promoter (42). In our hands, Dex-
mediated TLR2 induction was GR-dependent and accompanied
by DUSP1 induction (Supplementary Figure 5A). High
DUSP1 expression levels correlated with the repression of p38
phosphorylation (Supplementary Figures 5B,C), suggesting
that Dex-induced p38 inhibition may indeed play a role
in TLR2 upregulation. However, direct binding of GC/GR
complex to the TLR2 promoter might also contribute to the
overall effect.
Although GC-induced TLR2 upregulation has been suggested
to enhance inflammation, a link between TLR2 induction
and enhanced TLR2 responsiveness in immune cells has
not been shown so far. In contrast, TLR2 upregulation
has been reported to be paralleled by immunosuppression
(10, 12), which was confirmed by our study. The lack of
cytokine release upon TLR2 stimulation of GC-treated cells
has been explained by the downstream blockade of the
TLR2 receptor signaling and lack of TLR2 heterodimerization
partners (10, 12, 40, 45).
In addition to GC treatment, we showed that long-term LPS
exposure results in elevated TLR2 levels. Similar to GC-mediated
effects, chronic exposure to LPS represses pro-inflammatory
macrophage responses to recurring stimulation with LPS or
other TLR ligands. TLR signaling is inhibited on many levels
upon constant LPS stimulation, including downregulation of
TLR adapter molecules and upregulation of anti-inflammatory
factors (3, 20). In accordance, increased TLR2 expression did
not lead to improved TLR2-mediated inflammatory responses in
LPS-primed AMs in our study. Thus, we speculated that TLR2
induction by LPS and/or Dex might have anti-inflammatory
effects, e.g., by sTLR2 release.
Secretion of sTLR2 balances responses to both viral and
bacterial infections by binding a wide range of PAMPs and
DAMPs, thereby inhibiting the activation of cellular TLR2 (16).
We observed that sTLR2 was indeed produced by AMs, in
particular after LPS+Dex-treatment. sTLR2 was enriched after
activation of MPs, indicating that ectodomain shedding led to
sTLR2 production (17).
In addition, we detected an unexpected protein that resembled
full-length TLR2. In a previous study, Langjahr et al. (17) also
observed a full-size TLR2 glycoprotein in human macrophage
supernatant and hypothesized that it might correspond to the
full-length protein associated with membrane vesicles. This
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hypothesis is supported by our results showing that flTLR2
is present in isolated extracellular vesicles (EVs). Of note,
quantification of sTLR2 by ELISA, as used to analyze plasma
samples from LPS-exposed volunteers or septic patients (18,
19), would also detect vesicular flTLR2. Thus, it presently
remains elusive whether sTLR2, flTLR2, or both are present in
the circulation in response to LPS or sepsis. Elevated sTLR2
plasma levels have been suggested as a biomarker for infections
(18, 19). Therefore, it might be interesting to investigate
whether TLR2-EVs might serve as diagnostic markers to assess
disease progression, as currently discussed for various types of
EVs (47).
Under physiological and pathological conditions, almost
all cell types release cell-derived phospholipid-based bilayer
membrane vesicles equipped with functional surface and
membrane proteins and encapsulating various cargoes, including
proteins, cytokines, lipids, and nucleic acids (48, 49). They are
categorized as exosomes, microvesicles (MVs), and apoptotic
bodies based on their size, pathway of formation, and membrane
composition (49). Exosomes, which are 30–200 nm in size, derive
from the late endosome. In contrast, MVs are between 100 and
1,000 nm in diameter and are formed through outward budding
of the plasma membrane. Apoptotic bodies derived from
apoptotic cells are very heterogeneous in size and morphology,
and are, therefore, different from the other two EV subtypes
(36, 50). Since exosomes and microvesicles display a similar
appearance and composition as well as an overlapping size
distribution, it is difficult to define their origin once isolated (36).
Thus, we made no further distinction between these vesicle types
in this work.
Flow cytometric analysis confirmed the presence of TLR2
in EV preparations derived from LPS+Dex-treated AMs and
indicated an intact ligand binding ability. The overall inhibitory
function of these vesicles suggests that they may act as a decoy,
as previously shown for sTLR2 (17, 51). This decoy activity may
involve competition for not only the microbial ligand but also the
heterodimerization partners (51). Further studies are required
to elucidate the anti-inflammatory potential of TLR2-containing
EVs. These investigations might comprise more complex in vitro
(52) or in vivomodels (53, 54).
In summary, we showed for the first time that sTLR2
and full-length TLR2 are released by macrophages under
anti-inflammatory conditions. Our data suggest that
vesicle-bound flTLR2 has decoy functions, which may
contribute to immunosuppression induced by GCs and
chronic infections.
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